Episode Details
Back to Episodes
Daily Roundup | Jazz Buys Actio Biosciences in $1.3B Rare Epilepsy Deal
Published 1 month, 1 week ago
Description
Jazz Pharmaceuticals is paying $820 million upfront — up to $1.3 billion total — for Actio Biosciences and its first-in-class KCNT1 epilepsy drug ABS-1230. Plus: Sionna Therapeutics' SION-719 fails alongside Vertex's Trikafta in cystic fibrosis and shares fall nearly 92%, ITM receives a complete response letter for 177Lu-edotreotide in neuroendocrine tumors, Scholar Rock pulls a Novo Nordisk-owned Catalent site from the apitegromab SMA filing, Bristol Myers Squibb commits $2.3 billion to a Houston manufacturing campus, and a new executive order targets the MMR vaccine schedule amid rising measles cases. Visit us at thepharmacloseout.com.